18F-Fluoroethyl-L Tyrosine Positron Emission Tomography Radiomics in the Differentiation of Treatment-Related Changes from Disease Progression in Patients with Glioblastoma
Open Access
Abstract
The follow-up of glioma patients after therapeutic intervention remains a challenging topic, as therapy-related changes can emulate true progression in contrast-enhanced magnetic resonance imaging. 18F-fluoroethyl-tyrosine (18F-FET) is a radiopharmaceutical that accumulates in glioma cells due to an increased expression of L-amino acid transporters and, contrary to gadolinium, does not depend on blood–brain barrier disruption to reach tumoral cells. It has demonstrated a high diagnostic value in the differentiation of tumoral viability and pseudoprogression or any other therapy-related changes, especially when combining traditional visual analysis with modern radiomics. In this review, we aim to cover the potential role of 18F-FET positron emission tomography in everyday clinical practice when applied to the follow-up of patients after the first therapeutical intervention, early response evaluation, and the differential diagnosis between therapy-related changes and progression.Keywords
This publication has 64 references indexed in Scilit:
- Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastomaNeurology, 2011
- O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade GliomaJournal of Nuclear Medicine, 2011
- Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomasNeuro-Oncology, 2011
- Intensity-modulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issuesRadiotherapy and Oncology, 2010
- Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma NetworkJournal of Clinical Oncology, 2009
- Pseudoprogression and pseudoresponse in the treatment of gliomasCurrent Opinion in Neurology, 2009
- Pathological review of late cerebral radionecrosisBrain Tumor Pathology, 2008
- Biodisposition and metabolism of [18F]fluorocholine in 9L glioma cells and 9L glioma-bearing fisher ratsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applicationsNuclear Medicine and Biology, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005